

**ANNEX I**  
**SUMMARY OF PRODUCT CHARACTERISTICS**

## 1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Zulvac 1+8 Ovis suspension for injection for sheep

## 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each dose of 2 ml contains:

### Active substances:

Bluetongue virus, serotype 1, strain BTV-1/ALG2006/01 E1, inactivated.	RP* $\geq 1$
Bluetongue virus, serotype 8, strain BTV-8/BEL2006/02, inactivated.	RP* $\geq 1$

\*Relative Potency by a mice potency test compared to a reference vaccine that was shown efficacious in sheep.

### Adjuvants:

Aluminium hydroxide	4 mg (Al <sup>3+</sup> )
Saponin	0.4 mg

### Excipients:

Qualitative composition of excipients and other constituents	Quantitative composition if that information is essential for proper administration of the veterinary medicinal product
Thiomersal	0.2 mg
Potassium chloride	
Potassium dihydrogen phosphate	
Disodium hydrogen phosphate dodecahydrate	
Sodium chloride	
Water for injections	

Off-white or pink suspension.

## 3. CLINICAL INFORMATION

### 3.1 Target species

Sheep.

### 3.2 Indications for use for each target species

Active immunisation of sheep from 1.5 months of age for the prevention\* of viraemia caused by Bluetongue virus, serotypes 1 and 8.

\*(Cycling value (Ct)  $\geq 36$  by a validated RT-PCR method, indicating no presence of viral genome).

Onset of immunity: 3 weeks after completion of the primary vaccination scheme.

Duration of immunity: 1 year after completion of the primary vaccination scheme.

### **3.3 Contraindications**

None.

### **3.4 Special warnings**

Vaccinate healthy animals only.

No information is available on the use of the vaccine in seropositive animals including those with maternally derived antibodies.

### **3.5 Special precautions for use**

Special precautions for safe use in the target species:

Not applicable.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

Not applicable.

Special precautions for the protection of the environment:

Not applicable.

### **3.6 Adverse events**

Sheep:

Very common (>1 animal / 10 animals treated):	Injection site swelling <sup>1</sup> Injection site nodule <sup>2</sup>
Common (1 to 10 animals / 100 animals treated):	Elevated temperature <sup>3</sup>

<sup>1</sup>General swelling, for up to 7 days.

<sup>2</sup>Palpable nodules (subcutaneous granuloma), may persist for more than 48 days.

<sup>3</sup>Transient, up to 1.2 °C, for up to 24 hours.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or the national competent authority via the national reporting system. See the package leaflet for respective contact details.

### **3.7 Use during pregnancy, lactation or lay**

Pregnancy:

Can be used during pregnancy.

Lactation:

The safety of the vaccine has not been established during lactation.

Fertility:

The safety and the efficacy of the vaccine have not been established in breeding males. In this category of animals, the vaccine should be used only according to the benefit-risk assessment by the responsible veterinarian and/or national competent authorities on the current vaccination policies against Bluetongue virus (BTV).

### **3.8 Interaction with other medicinal products and other forms of interaction**

No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case-by-case basis.

### **3.9 Administration routes and dosage**

Subcutaneous use.

**Primary vaccination:**

Administer one dose of 2 ml according to the following vaccination scheme:

1<sup>st</sup> dose: from 1.5 months of age.

2<sup>nd</sup> dose: after 3 weeks.

**Revaccination:**

Any revaccination scheme should be agreed by the competent authority or by the responsible veterinarian, taking into account the local epidemiological situation.

**Method of administration:**

Apply usual aseptic procedures.

Shake gently immediately before use.

Avoid bubble formation, as this can be irritating at the site of injection.

The entire content of the vial should be used immediately after broaching and during the same procedure.

In order to avoid accidental contamination of the vaccine during use, it is recommended to use a multi-injection type vaccination system when larger dose presentations are used.

### **3.10 Symptoms of overdose (and where applicable, emergency procedures and antidotes)**

A transient increase in rectal temperature, not exceeding 0.6 °C, may occur during the 24 hours following administration of a 2-fold overdose.

Administration of a 2-fold overdose may be followed in most animals by a local reaction at the injection site. These reactions take the form in most cases of a general swelling of the injection site (persisting for not more than 9 days) or of palpable nodules (subcutaneous granuloma, possibly persisting for more than 63 days).

### **3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance**

Any person intending to manufacture, import, possess, distribute, sell, supply and use this veterinary medicinal product must first consult the relevant Member State's competent authority on the current vaccination policies, as these activities may be prohibited in a Member State on the whole or part of its territory pursuant to national legislation.

### **3.12 Withdrawal periods**

Zero days.

## **4. IMMUNOLOGICAL INFORMATION**

### **4.1 ATCvet code : QI04AA02**

To stimulate active immunity against Bluetongue virus, serotypes 1 and 8 in sheep.

## **5. PHARMACEUTICAL PARTICULARS**

### **5.1 Major incompatibilities**

Do not mix with any other veterinary medicinal product.

### **5.2 Shelf life**

Shelf life of the veterinary medicinal product as packaged for sale: 1 year.  
Shelf life after first opening the immediate packaging: use immediately.

### **5.3 Special precautions for storage**

Store and transport refrigerated (2 °C – 8 °C).  
Do not freeze.  
Protect from light.

### **5.4 Nature and composition of immediate packaging**

High density polyethylene (HDPE) vials of 20, 100 or 240 ml with chlorobutyl elastomer stopper and aluminium seal containing 10, 50 or 120 doses of vaccine.

#### Pack sizes:

Cardboard box with 1 vial of 10 doses (20 ml).  
Cardboard box with 1 vial of 50 doses (100 ml).  
Cardboard box with 1 vial of 120 doses (240 ml).

Not all pack sizes may be marketed.

### **5.5 Special precautions for the disposal of unused veterinary medicinal products or waste materials derived from the use of such products**

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.

## **6. NAME OF THE MARKETING AUTHORISATION HOLDER**

Zoetis Belgium

## **7. MARKETING AUTHORISATION NUMBER(S)**

EU/2/11/120/001-003

## **8. DATE OF FIRST AUTHORISATION**

Date of first authorisation: 14/03/2011.

**9. DATE OF THE LAST REVISION OF THE SUMMARY OF THE PRODUCT CHARACTERISTICS**

{MM/YYYY}

**10. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCTS**

Veterinary medicinal product subject to prescription.

Detailed information on this veterinary medicinal product is available in the [Union Product Database \(https://medicines.health.europa.eu/veterinary\)](https://medicines.health.europa.eu/veterinary).

## **ANNEX II**

### **OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION**

None.

**ANNEX III**  
**LABELLING AND PACKAGE LEAFLET**

## **A. LABELLING**

**PARTICULARS TO APPEAR ON THE OUTER PACKAGE****CARDBOARD BOX (20 ML, 100 ML OR 240 ML)****1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Zulvac 1+8 Ovis Suspension for injection.

**2. STATEMENT OF ACTIVE SUBSTANCES**

Each dose of 2 ml contains:

Bluetongue virus, serotype 1, strain BTV-1/ALG2006/01 E1, inactivated.

Bluetongue virus, serotype 8, strain BTV-8/BEL2006/02, inactivated.

**3. PACKAGE SIZE**

20 ml (10 doses)

100 ml (50 doses)

240 ml (120 doses)

**4. TARGET SPECIES**

Sheep.

**5. INDICATIONS****6. ROUTES OF ADMINISTRATION**

Subcutaneous use.

**7. WITHDRAWAL PERIODS**

Withdrawal periods: Zero days.

**8. EXPIRY DATE**

Exp. {mm/yyyy}

Once broached use immediately.

**9. SPECIAL STORAGE PRECAUTIONS**

Store and transport refrigerated.

Do not freeze.

Protect from light.

**10. THE WORDS "READ THE PACKAGE LEAFLET BEFORE USE"**

Read the package leaflet before use.

**11. THE WORDS "FOR ANIMAL TREATMENT ONLY"**

For animal treatment only.

**12. THE WORDS "KEEP OUT OF THE SIGHT AND REACH OF CHILDREN"**

Keep out of the sight and reach of children.

**13. NAME OF THE MARKETING AUTHORISATION HOLDER**

Zoetis Belgium

**14. MARKETING AUTHORISATION NUMBERS**

EU/2/11/120/001 (20 ml)

EU/2/11/120/002 (100 ml)

EU/2/11/120/003 (240 ml)

**15. BATCH NUMBER**

Lot {number}

**PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE****VIAL (100 ML OR 240 ML)****1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Zulvac 1+8 Ovis Suspension for injection.

**2. STATEMENT OF ACTIVE SUBSTANCES**

Each dose of 2 ml contains:

Bluetongue virus, serotype 1, strain BTV-1/ALG2006/01 E1, inactivated.

Bluetongue virus, serotype 8, strain BTV-8/BEL2006/02, inactivated.

100 ml (50 doses)

240 ml (120 doses)

**3. TARGET SPECIES**

Sheep.

**4. ROUTES OF ADMINISTRATION**

Subcutaneous use.

Read the package leaflet before use.

**5. WITHDRAWAL PERIODS**

Withdrawal periods: Zero days.

**6. EXPIRY DATE**

Exp. {mm/yyyy}

Once broached use immediately.

**7. SPECIAL STORAGE PRECAUTIONS**

Store and transport refrigerated.

Do not freeze.

Protect from light.

**8. NAME OF THE MARKETING AUTHORISATION HOLDER**

Zoetis Belgium

<b>9. BATCH NUMBER</b>
------------------------

Lot {number}

**MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS****VIAL (20 ML)****1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Zulvac 1+8 Ovis

**2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES**

Bluetongue virus, serotype 1, strain BTV-1/ALG2006/01 E1, inactivated.  
Bluetongue virus, serotype 8, strain BTV-8/BEL2006/02, inactivated.

20 ml (10 doses)

**3. BATCH NUMBER**

Lot {number}

**4. EXPIRY DATE**

Exp. {mm/yyyy}

Once broached use immediately.

**B. PACKAGE LEAFLET**

## PACKAGE LEAFLET

### 1. Name of the veterinary medicinal product

Zulvac 1+8 Ovis suspension for injection for sheep

### 2. Composition

Each dose of 2 ml contains:

#### Active substances:

Bluetongue virus, serotype 1, strain BTV-1/ALG2006/01 E1, inactivated. RP\*  $\geq 1$   
Bluetongue virus, serotype 8, strain BTV-8/BEL2006/02, inactivated. RP\*  $\geq 1$

\*Relative Potency by a mice potency test compared to a reference vaccine that was shown efficacious in sheep.

#### Adjuvants:

Aluminium hydroxide	4 mg (Al <sup>3+</sup> )
Saponin	0.4 mg

#### Excipients:

Thiomersal	0.2 mg
------------	--------

Off-white or pink suspension.

### 3. Target species

Sheep.

### 4. Indications for use

Active immunisation of sheep from 1.5 months of age for the prevention\* of viraemia caused by Bluetongue virus, serotypes 1 and 8.

\*(Cycling value (Ct)  $\geq 36$  by a validated RT-PCR method, indicating no presence of viral genome)

Onset of immunity: 3 weeks after completion of the primary vaccination scheme.

Duration of immunity: 1 year after completion of the primary vaccination scheme.

### 5. Contraindications

None.

### 6. Special warnings

#### Special warnings:

Vaccinate healthy animals only.

No information is available on the use of the vaccine in seropositive animals including those with maternally derived antibodies.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

Not applicable.

Pregnancy:

Can be used during pregnancy.

Lactation:

The safety of the vaccine has not been established during lactation.

Fertility:

The safety and the efficacy of the vaccine have not been established in breeding males. In this category of animals, the vaccine should be used only according to the benefit-risk assessment by the responsible veterinarian and/or national competent authorities on the current vaccination policies against Bluetongue virus (BTV).

Interaction with other medicinal products and other forms of interaction:

No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case-by-case basis.

Overdose:

A transient increase in rectal temperature, not exceeding 0.6 °C, may occur during the 24 hours following administration of a 2-fold overdose.

Administration of a 2-fold overdose may be followed in most animals by a local reaction at the injection site. These reactions take the form in most cases of a general swelling of the injection site (persisting for not more than 9 days) or of palpable nodules (subcutaneous granuloma, possibly persisting for more than 63 days).

Special restrictions for use and special conditions for use:

Any person intending to manufacture, import, possess, distribute, sell, supply and use this veterinary medicinal product must first consult the relevant Member State's competent authority on the current vaccination policies, as these activities may be prohibited in a Member State on the whole or part of its territory pursuant to national legislation.

Major incompatibilities:

Do not mix with any other veterinary medicinal products.

## 7. Adverse events

Sheep:

Very common (>1 animal / 10 animals treated):
Injection site swelling <sup>1</sup>
Injection site nodule <sup>2</sup>
Common (1 to 10 animals / 100 animals treated):
Elevated temperature <sup>3</sup>

<sup>1</sup>General swelling, for up to 7 days.

<sup>2</sup>Palpable nodules (subcutaneous granuloma), may persist for more than 48 days.

<sup>3</sup>Transient, up to 1.2 °C, for up to 24 hours.

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report

any adverse events to the marketing authorisation holder using the contact details at the end of this leaflet, or via your national reporting system: {national system details}.

## **8. Dosage for each species, routes and method of administration**

Subcutaneous use.

### Primary vaccination:

Administer one dose of 2 ml according to the following vaccination scheme:

1<sup>st</sup> dose: from 1.5 months of age.

2<sup>nd</sup> dose: after 3 weeks.

### Revaccination:

Any revaccination scheme should be agreed by the competent authority or by the responsible veterinarian, taking into account the local epidemiological situation.

## **9. Advice on correct administration**

Apply usual aseptic procedures.

Shake gently immediately before use.

Avoid bubble formation, as this can be irritating at the site of injection.

The entire content of the vial should be used immediately after broaching and during the same procedure.

In order to avoid accidental contamination of the vaccine during use, it is recommended to use a multi-injection type vaccination system when larger dose presentations are used.

## **10. Withdrawal periods**

Zero days.

## **11. Special storage precautions**

Keep out of the sight and reach of children.

Store and transport refrigerated (2 °C – 8 °C).

Do not freeze.

Protect from light.

Do not use this veterinary medicinal product after the expiry date which is stated on the label and carton after Exp. The expiry date refers to the last day of that month.

Shelf life after first opening the immediate packaging: use immediately.

## **12. Special precautions for disposal**

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any applicable national collection systems. These measures should help to protect the environment.

Ask your veterinary surgeon or pharmacist how to dispose of medicines no longer required.

### **13. Classification of veterinary medicinal products**

Veterinary medicinal product subject to prescription.

### **14. Marketing authorisation numbers and pack sizes**

EU/2/11/120/001-003

Cardboard box with 1 vial of 10 doses (20 ml).  
Cardboard box with 1 vial of 50 doses (100 ml).  
Cardboard box with 1 vial of 120 doses (240 ml).

Not all pack sizes may be marketed.

### **15. Date on which the package leaflet was last revised**

{MM/YYYY}

Detailed information on this veterinary medicinal product is available in the Union Product Database (<https://medicines.health.europa.eu/veterinary>).

### **16. Contact details**

Marketing authorisation holder and contact details to report suspected adverse events:

Zoetis Belgium  
Rue Laid Burniat 1  
1348 Louvain-La-Neuve  
Belgium

**België/Belgique/Belgien**  
Tél/Tel: +32 (0) 800 99 189  
[pharmvig-belux@zoetis.com](mailto:pharmvig-belux@zoetis.com)

**Република България**  
Тел: +359 888 51 30 30  
[zoetisromania@zoetis.com](mailto:zoetisromania@zoetis.com)

**Česká republika**  
Tel: +420 257 101 111  
[infovet.cz@zoetis.com](mailto:infovet.cz@zoetis.com)

**Danmark**  
Tlf: +45 70 20 73 05  
[adr.scandinavia@zoetis.com](mailto:adr.scandinavia@zoetis.com)

**Deutschland**  
Tel: +49 30 2020 0049  
[tierarzneimittelsicherheit@zoetis.com](mailto:tierarzneimittelsicherheit@zoetis.com)

**Eesti**  
Tel: +370 610 05088  
[zoetis.estonia@zoetis.com](mailto:zoetis.estonia@zoetis.com)

**Lietuva**  
Tel: +370 610 05088  
[zoetis.lithuania@zoetis.com](mailto:zoetis.lithuania@zoetis.com)

**Luxembourg/Luxemburg**  
Tél/Tel: +32 (2) 746 80 11  
[pharmvig-belux@zoetis.com](mailto:pharmvig-belux@zoetis.com)

**Magyarország**  
Tel.: +36 1 224 5200  
[hungary.info@zoetis.com](mailto:hungary.info@zoetis.com)

**Malta**  
Tel: +356 21 465 797  
[info@agrimedltd.com](mailto:info@agrimedltd.com)

**Nederland**  
Tel: +31 (0)10 714 0900  
[pharmvig-nl@zoetis.com](mailto:pharmvig-nl@zoetis.com)

**Norge**  
Tlf: +47 23 29 86 80  
[adr.scandinavia@zoetis.com](mailto:adr.scandinavia@zoetis.com)

**Ελλάδα**  
Τηλ: +30 210 6791900  
[infogr@zoetis.com](mailto:infogr@zoetis.com)

**España**  
Tel: +34 91 4191900  
[regulatory.spain@zoetis.com](mailto:regulatory.spain@zoetis.com)

**France**  
Tél: +33 (0)800 73 00 65  
[contacteznous@zoetis.com](mailto:contacteznous@zoetis.com)

**Hrvatska**  
Tel: +385 1 6441 462  
[pv.westernbalkans@zoetis.com](mailto:pv.westernbalkans@zoetis.com)

**Ireland**  
Tel: +353 (0) 1 256 9800  
[pvsupportireland@zoetis.com](mailto:pvsupportireland@zoetis.com)

**Ísland**  
Sími: +354 540 8000  
[icepharma@icepharma.is](mailto:icepharma@icepharma.is)

**Italia**  
Tel: +39 06 3366 8111  
[farmacovigilanza.italia@zoetis.com](mailto:farmacovigilanza.italia@zoetis.com)

**Κύπρος**  
Τηλ: +30 210 6791900  
[infogr@zoetis.com](mailto:infogr@zoetis.com)

**Latvija**  
Tel: +370 610 05088  
[zoetis.latvia@zoetis.com](mailto:zoetis.latvia@zoetis.com)

**Manufacturer responsible for batch release:**  
Zoetis Manufacturing & Research Spain S.L.  
Carretera De Camprodón S/n  
La Vall De Bianya  
17813 Girona  
Spain

**Österreich**  
Tel: +43 (0)1 2701100 100  
[tierarzneimittelsicherheit@zoetis.com](mailto:tierarzneimittelsicherheit@zoetis.com)

**Polska**  
Tel.: +48 22 2234800  
[pv.poland@zoetis.com](mailto:pv.poland@zoetis.com)

**Portugal**  
Tel: +351 21 042 72 00  
[zoetis.portugal@zoetis.com](mailto:zoetis.portugal@zoetis.com)

**România**  
Tel: +40785019479  
[zoetisromania@zoetis.com](mailto:zoetisromania@zoetis.com)

**Slovenija**  
Tel: +385 1 6441 462  
[pv.westernbalkans@zoetis.com](mailto:pv.westernbalkans@zoetis.com)

**Slovenská republika**  
Tel: +420 257 101 111  
[infovet.cz@zoetis.com](mailto:infovet.cz@zoetis.com)

**Suomi/Finland**  
Puh/Tel: +358 10 336 7000  
[laaketurva@zoetis.com](mailto:laaketurva@zoetis.com)

**Sverige**  
Tel: +46 (0) 76 760 0677  
[adr.scandinavia@zoetis.com](mailto:adr.scandinavia@zoetis.com)

**United Kingdom (Northern Ireland)**  
Tel: +353 (0) 1 256 9800  
[pvsupportireland@zoetis.com](mailto:pvsupportireland@zoetis.com)

## 17. Other information

To stimulate active immunity against Bluetongue virus, serotypes 1 and 8 in sheep.